Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Gene signatures and prognostic values of m6A regulators in clear cell renal cell carcinoma - a retrospective study using TCGA database.

Zhou J, Wang J, Hong B, Ma K, Xie H, Li L, Zhang K, Zhou B, Cai L, Gong K.

Aging (Albany NY). 2019 Mar 15;11(6):1633-1647. doi: 10.18632/aging.101856.

2.

ITGA2B and ITGA8 are predictive of prognosis in clear cell renal cell carcinoma patients.

Lu X, Wan F, Zhang H, Shi G, Ye D.

Tumour Biol. 2016 Jan;37(1):253-62. doi: 10.1007/s13277-015-3792-5. Epub 2015 Jul 22.

PMID:
26198048
3.

RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.

Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, Wong CC, Ng IO, Wong CM.

Hepatology. 2018 Jun;67(6):2254-2270. doi: 10.1002/hep.29683. Epub 2018 Apr 19.

PMID:
29171881
4.

Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma.

Peng Q, Wang L, Zhao D, Lv Y, Wang H, Chen G, Wang J, Xu W.

J Cancer. 2019 Jan 29;10(5):1237-1251. doi: 10.7150/jca.28662. eCollection 2019.

5.

N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1α signalling axis.

Zhuang C, Zhuang C, Luo X, Huang X, Yao L, Li J, Li Y, Xiong T, Ye J, Zhang F, Gui Y.

J Cell Mol Med. 2019 Mar;23(3):2163-2173. doi: 10.1111/jcmm.14128. Epub 2019 Jan 16.

6.

A four-gene signature predicts survival in clear-cell renal-cell carcinoma.

Dai J, Lu Y, Wang J, Yang L, Han Y, Wang Y, Yan D, Ruan Q, Wang S.

Oncotarget. 2016 Dec 13;7(50):82712-82726. doi: 10.18632/oncotarget.12631.

7.

Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.

de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK.

Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.

8.

N6-methyladenosine modification and the YTHDF2 reader protein play cell type specific roles in lytic viral gene expression during Kaposi's sarcoma-associated herpesvirus infection.

Hesser CR, Karijolich J, Dominissini D, He C, Glaunsinger BA.

PLoS Pathog. 2018 Apr 16;14(4):e1006995. doi: 10.1371/journal.ppat.1006995. eCollection 2018 Apr.

9.

The N6-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy.

Dorn LE, Lasman L, Chen J, Xu X, Hund TJ, Medvedovic M, Hanna JH, van Berlo JH, Accornero F.

Circulation. 2019 Jan 22;139(4):533-545. doi: 10.1161/CIRCULATIONAHA.118.036146.

10.

Long Non-Coding RNA LUCAT1 Promotes Proliferation and Invasion in Clear Cell Renal Cell Carcinoma Through AKT/GSK-3β Signaling Pathway.

Zheng Z, Zhao F, Zhu D, Han J, Chen H, Cai Y, Chen Z, Xie W.

Cell Physiol Biochem. 2018;48(3):891-904. doi: 10.1159/000491957. Epub 2018 Jul 20.

11.

SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.

Du Y, Hou G, Zhang H, Dou J, He J, Guo Y, Li L, Chen R, Wang Y, Deng R, Huang J, Jiang B, Xu M, Cheng J, Chen GQ, Zhao X, Yu J.

Nucleic Acids Res. 2018 Jun 1;46(10):5195-5208. doi: 10.1093/nar/gky156.

12.

Changes of N6-methyladenosine modulators promote breast cancer progression.

Wu L, Wu D, Ning J, Liu W, Zhang D.

BMC Cancer. 2019 Apr 5;19(1):326. doi: 10.1186/s12885-019-5538-z.

13.

The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells.

Taketo K, Konno M, Asai A, Koseki J, Toratani M, Satoh T, Doki Y, Mori M, Ishii H, Ogawa K.

Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.

PMID:
29345285
14.

IDUA, NDST1, SAP30L, CRYBA4, and SI as novel prognostic signatures clear cell renal cell carcinoma.

Zeng MH, Qiu JG, Xu Y, Zhang XH.

J Cell Physiol. 2019 Feb 28. doi: 10.1002/jcp.28297. [Epub ahead of print]

PMID:
30820959
15.

N6-methyladenosine modification and METTL3 modulate enterovirus 71 replication.

Hao H, Hao S, Chen H, Chen Z, Zhang Y, Wang J, Wang H, Zhang B, Qiu J, Deng F, Guan W.

Nucleic Acids Res. 2019 Jan 10;47(1):362-374. doi: 10.1093/nar/gky1007.

16.
17.

N6-Methyladenosine in RNA and DNA: An Epitranscriptomic and Epigenetic Player Implicated in Determination of Stem Cell Fate.

Ji P, Wang X, Xie N, Li Y.

Stem Cells Int. 2018 Oct 10;2018:3256524. doi: 10.1155/2018/3256524. eCollection 2018. Review.

18.

Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.

Xiao W, Xiong Z, Yuan C, Bao L, Liu D, Yang X, Li W, Tong J, Qu Y, Liu L, Xiao H, Yang H, Zhang X, Chen K.

Oncotarget. 2017 Oct 23;8(55):94819-94833. doi: 10.18632/oncotarget.21999. eCollection 2017 Nov 7.

19.

m6A-Driver: Identifying Context-Specific mRNA m6A Methylation-Driven Gene Interaction Networks.

Zhang SY, Zhang SW, Liu L, Meng J, Huang Y.

PLoS Comput Biol. 2016 Dec 27;12(12):e1005287. doi: 10.1371/journal.pcbi.1005287. eCollection 2016 Dec.

20.

N6-methyladenosine contributes to cellular phenotype in a genetically-defined model of breast cancer progression.

Fry NJ, Law BA, Ilkayeva OR, Carraway KR, Holley CL, Mansfield KD.

Oncotarget. 2018 Jul 27;9(58):31231-31243. doi: 10.18632/oncotarget.25782. eCollection 2018 Jul 27.

Supplemental Content

Support Center